Show Summary Details
Page of

Molecularly Targeted Therapy for Mendelian Disorders 

Molecularly Targeted Therapy for Mendelian Disorders
Chapter:
Molecularly Targeted Therapy for Mendelian Disorders
Author(s):

Mark Davies

and Julian Roy Sampson

DOI:
10.1093/med/9780199896028.003.0049
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 30 October 2020

The era of genomic medicine brings many new opportunities for treatment of genetic diseases where few existed previously. In Mendelian disorders the essentially causal relationship between mutation and disease provides the rationale for very specific therapies targeted to pathology at the DNA, RNA or protein level. The development of such therapies for rare Mendelian disorders often requires novel approaches in terms of biology, trial design and regulatory requirements and the emerging field of molecularly targeted therapy for these disorders has been characterised by setbacks and disappointments as well as stunning successes. Examples include exon skipping for X-linked Duchenne/ Becker muscular dustrophy; mTOR inhibitors for angioleiomyomas in tuberous sclerosis complex, enzyme replacement for metabolic storage disorders like Fabry, Gaucher and Pompe and new developments for Huntington’s disease.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.